First-in-Human VT3989 Shows Early Activity in Mesothelioma — First Clinical Proof of Concept for Targeting Hippo–YAP–TEAD
VT3989, an oral TEAD palmitoylation inhibitor, produced objective responses in refractory mesothelioma with manageable toxicity and establishes first clinical proof of concept for targeting the Hippo–YAP–TEAD pathway.